An observational study in Pulmonary Arterial Hypertension, sponsored by AOP Orphan Pharmaceuticals AG. Enrolling by invitation at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by AOP Orphan Pharmaceuticals AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Pulmonary Arterial Hypertension with a site in Germany — 13 open to participants now, 18 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Germany.
Among the 119 studies in Pulmonary Arterial Hypertension with a site in Germany, this one is the 10th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2024, is one of 17 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 111th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →13 of the 119 studies in Pulmonary Arterial Hypertension with a site in Germany are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
Inhibikase Therapeutics · Sites in Germany, United States, Argentina and 11 more countries
Ages 18–75
AllRock Bio, Inc. · Sites in Germany, United States, Australia and 6 more countries
Ages 18–80
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 15 more countries
Ages 18–100 · Healthy volunteers
Gossamer Bio USA, Inc. · Sites in Germany, United States, Argentina and 27 more countries
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 39 · Phase 3 46 · Phase 4 10
First in 2002; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 101 across the 102 interventional studies, 120 across the 17 observational. Of the 98 that completed or were terminated, 62 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 119 have an industry lead sponsor. The 10 most frequent:
AOP Orphan Pharmaceuticals AG is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
AOP Orphan Pharmaceuticals AG has 4 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Arterial Hypertension with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT01347216Technische Universität DresdenCOMPERA / COMPERA-KIDS | 2026-12-31 |
| NCT07175038AllRock Bio, Inc.A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 119 studies in Pulmonary Arterial Hypertension with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.
The primary objective of this non-interventional follow-up study is to assess the long-term real-world clinical outcomes, including disease progression and survival rates, in patients who initially participated in and completed the randomized TripleTRE trial.
Planned observation duration per patient is a minimum of 3 years.
The study population will consist of patients who participated in the TripleTRE study and who have not been lost to follow-up and have given a written informed consent for their participation in the NIS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Patients previously participating in the randomized TripleTRE trial who are able and willing to provide a signed for study participation in NIS
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all patients previously treated within the TripleTRE trial who are willing to participate in this NIS
Time to death or lung transplantation
Time frame: up to year 3
Time to first clinical worsening
clinical worsening is defined as fulfilling on of the following criteria: * PAH related death (including all deaths where PAH cannot be excluded as cause) * Lung transplantation due to PAH * PAH-related hospitalization * Post baseline decrease in 6MWD by 15% * Post baseline worsening of WHO FC
Time frame: up to year 3
Total number of clinical worsenings
clinical worsening is defined as fulfilling on of the following criteria: * PAH related death (including all deaths where PAH cannot be excluded as cause) * Lung transplantation due to PAH * PH-related hospitalization * Post baseline decrease in 6MWD by 15% * Post baseline worsening of WHO FC
Time frame: up to year 3
Long-term change in 6MWD
6-Minute Walking Distance (6MWD) will be measured in meters
Time frame: up to year 3
Long-term change in PAH treatment regimens
any change or addition of new PH medication including dosing in time
Time frame: up to year 3
Long-term change in risk status
Risk status measured by simplified four-strata risk-assessment tool
Time frame: up to year 3
Long-term change in WHO FC
World Health Organization Functional Class (WHO FC) is categorized from I (no symptoms) to IV (severe dyspnea and symptoms)
Time frame: up to year 3
Long-term change in BDS
BDS - Borg Dyspnea Score, ranging from 0 (no exertion) to 10 (maximum)
Time frame: up to year 3
Long-term change in NT-proBNP/BNP
NT-proBNP/BNP: N-terminal pro Brain Natriuretic Peptide
Time frame: up to year 3
Long-term change in Pulmonary Vascular Resistance (PVR)
PVR to be measured in WU Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in mean Pulmonary Arterial Pressure (mPAP)
mPAP to be measured in mmHg Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Right Atrial Pressure (RAP)
RAP to be measured in mmHg Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in mean Right Atrial Pressure (mRAP)
mean Right Atrial Pressure (mRAP) to be measured in mmHg Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Cardiac Index (CI)
Cardiac index (CI) measured in liters per minute per square meter Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Cardiac Output (CO)
Cardiac output (CO) measured in liters per minute Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Pulmonary capillary wedge pressure (PCWP)
Pulmonary capillary wedge pressure (PCWP) measured in mmHg Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Stroke volume index (SVI)
Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in RV-PA coupling
RV-PA coupling estimated by the ratio of tricuspid annular plane systolic excursion by pulmonary artery systolic pressure Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in RV end-diastolic area (RVEDA)
RV end-diastolic area (RVEDA) measured in square centimeters Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in RV end-systolic area (RVESA)
RV end-systolic area (RVESA) measured in square centimeters Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in RV fractional area change (RVFAC)
RV fractional area change (RVFAC) calculated in % Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Right Atrium (RA) area
Right Atrium (RA) area in square centimeters Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Pericardial effusion
Pericardial effusion assessment will be done and rated as yes/no Parameter will be collected according to clinical routine
Time frame: up to year 3
Long-term change in Right ventricular ejection fraction (RVEF)
Parameter will be collected according to clinical routine
Time frame: up to year 3
Frequency and seriousness of adverse events (AE) and adverse drug reactions (ADR)
This includes: * Adverse events (S)AEs * Adverse drug reactions (S)ADRs related to any of PAH treatments * Adverse events related to underlying diagnosis, PAH
Time frame: up to year 3
Long-term change in QoL using European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) questionnaire
The EQ-5D-5L questionnaire consists of 2 parts - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. It should be noted that the numerals 1-5 have no arithmetic properties and should not be used as a cardinal score.
Time frame: up to year 3
Long-term change in QoL using PAH-specific emPHasis-10 questionnaire
Emphasis meaning something of special importance or significance. Please translate using the most appropriate term. The PH in emPHasis represents the condition Pulmonary Hypertension. The number 10 refers to the number of items in the questionnaire. This questionnaire is designed to determine how Pulmonary Hypertension (PH) affects patient's life. It refers to how PH affects or the impact that PH has on the patient's life.
Time frame: up to year 3
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jun 2030, 71 months after the start.
Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 71 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
AOP Orphan Pharmaceuticals AG